AbbVie Receives NDA for Atogepant, Aims to Stop Migraines in Their Tracks

There was new hope on Tuesday for millions of migraine sufferers as AbbVie announced the U.S. Food and Drug Administration (FDA) acceptance of its New Drug Application (NDA) for atogepant, which aims to prevent the often debilitating condition.